Compare VERI & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERI | INO |
|---|---|---|
| Founded | 2014 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7M | 100.4M |
| IPO Year | 2017 | 1999 |
| Metric | VERI | INO |
|---|---|---|
| Price | $1.44 | $0.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $7.00 | $6.75 |
| AVG Volume (30 Days) | 2.1M | ★ 4.0M |
| Earning Date | 04-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $92,637,000.00 | $42,220,086.00 |
| Revenue This Year | $52.20 | $20,156.19 |
| Revenue Next Year | $3.06 | $421.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $0.98 | $0.56 |
| 52 Week High | $9.42 | $2.86 |
| Indicator | VERI | INO |
|---|---|---|
| Relative Strength Index (RSI) | 65.59 | 33.01 |
| Support Level | $1.27 | $0.56 |
| Resistance Level | $1.54 | $1.24 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 88.46 | 31.29 |
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.